Equities

Procept Biorobotics Corp

PRCT:NMQ

Procept Biorobotics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)93.61
  • Today's Change0.005 / 0.01%
  • Shares traded35.31k
  • 1 Year change+164.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 14:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

  • Revenue in USD (TTM)199.84m
  • Net income in USD-100.06m
  • Incorporated2021
  • Employees626.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Warby Parker Inc742.53m-32.56m2.78bn2.14k--8.25245.173.75-0.2731-0.27316.202.801.225.70818.21346,975.20-5.37---6.78--55.3257.49-4.39-14.532.06--0.00--11.9819.6742.75------
LivaNova PLC1.24bn23.68m2.79bn2.90k120.492.1341.072.240.42590.425922.8124.130.51192.476.42428,185.900.9777-6.011.12-7.4267.7866.991.91-13.562.872.460.3234--12.890.8278120.34---1.64--
Inari Medical Inc574.50m-78.58m2.91bn1.30k--6.67--5.06-1.35-1.359.907.440.92211.597.46441,921.50-12.61-0.5941-15.24-0.669686.8289.06-13.68-0.62951.40--0.00--28.73135.4094.41--52.46--
Neogen Corp912.20m-23.53m3.25bn2.92k--1.0434.443.56-0.1086-0.10864.2114.470.20132.715.98312,718.20-0.51931.38-0.53461.4449.5648.23-2.584.312.791.030.22150.0012.3717.4158.81--50.02--
Envista Holdings Corp2.50bn-1.34bn3.70bn12.80k--1.20--1.48-7.77-7.7714.5117.860.41064.216.19195,570.30-21.931.94-25.272.3454.2057.65-53.425.291.773.130.31630.00-0.1012-2.04-142.10---4.22--
DENTSPLY SIRONA Inc3.90bn-413.00m3.73bn15.00k--1.50--0.9567-2.07-2.0718.9112.530.56412.945.91260,000.00-5.93-1.14-7.41-1.3252.1853.65-10.51-2.510.84443.210.471--1.10-0.107186.11---4.549.86
Guardant Health Inc692.26m-512.41m4.03bn1.78k------5.83-4.24-4.245.70-0.4880.4153.687.81389,126.50-30.72-22.26-35.19-24.5960.3164.62-74.02-97.075.85-8.041.06--25.4544.1426.76--0.2786--
ICU Medical Inc2.34bn-111.01m4.11bn14.00k--2.0136.121.76-4.57-4.5796.3183.760.53912.1613.94167,149.80-2.561.46-2.901.6532.8734.11-4.742.231.030.51580.43820.00-0.915410.0460.08---1.45--
Haemonetics Corporation1.36bn123.81m4.30bn3.66k35.534.9018.413.162.412.4126.4817.440.60011.877.02372,224.005.465.026.196.0754.0251.749.108.112.0927.430.58230.0012.016.231.8716.40-11.04--
Integer Holdings Corp1.68bn114.44m4.63bn10.50k42.582.8620.932.763.243.2247.8748.330.55944.935.14160,023.803.813.284.103.5327.0626.946.816.402.094.110.40280.0016.035.6238.719.3321.71--
Procept Biorobotics Corp199.84m-100.06m5.06bn626.00--20.23--25.32-1.95-1.953.894.630.50261.833.86319,238.00-25.16---28.58--57.39---50.07--5.07--0.1758--81.55---21.51------
Inspire Medical Systems Inc755.59m33.05m5.66bn1.01k173.448.12148.827.491.091.0925.1523.251.052.469.37747,372.904.60-11.275.12-12.6084.7784.474.37-13.576.94--0.00--53.1965.3252.87--148.37--
Stevanato Group SpA1.14bn119.48m5.95bn5.64k44.163.8929.585.220.44490.44494.235.050.52842.752.66202,254.005.54--7.39--29.20--10.48--1.2148.530.2148--10.34--1.95------
Merit Medical Systems Inc1.33bn120.04m6.14bn6.95k51.604.6428.194.632.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Lantheus Holdings Inc1.50bn427.61m6.29bn834.0015.045.3312.844.206.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Data as of Nov 25 2024. Currency figures normalised to Procept Biorobotics Corp's reporting currency: US Dollar USD

Institutional shareholders

44.49%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 20247.23m13.86%
The Vanguard Group, Inc.as of 30 Sep 20244.72m9.04%
BlackRock Fund Advisorsas of 30 Sep 20243.27m6.27%
AllianceBernstein LPas of 30 Sep 20241.53m2.94%
Loomis, Sayles & Co. LPas of 30 Sep 20241.24m2.38%
SSgA Funds Management, Inc.as of 30 Sep 20241.18m2.26%
Geode Capital Management LLCas of 30 Sep 20241.11m2.12%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20241.03m1.98%
CPMG, Inc.as of 30 Sep 2024958.33k1.84%
Wellington Management Co. LLPas of 30 Sep 2024940.48k1.80%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.